• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新型抗真菌药L-743,872（一种 pneumocandin）对唑类敏感及耐药念珠菌属的体外活性

In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species.

作者信息

Vazquez J A, Lynch M, Boikov D, Sobel J D

机构信息

Department of Medicine, Wayne State University School of Medicine, and Detroit Veterans Administration Medical Center, Michigan, USA.

出版信息

Antimicrob Agents Chemother. 1997 Jul;41(7):1612-4. doi: 10.1128/AAC.41.7.1612.

DOI:10.1128/AAC.41.7.1612
PMID:9210698
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC163972/
Abstract

The in vitro activity of a new pneumocandin, L-743,872, was evaluated with 108 strains of Candida and compared with the activities of various antifungals. L-743,872 demonstrated the best activity against azole-susceptible and -resistant strains of C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, and C. kefyr and less activity against C. krusei, C. lusitaniae, and C. guilliermondii.

摘要

用108株念珠菌评估了一种新型肺孢子菌素L-743,872的体外活性，并与各种抗真菌药物的活性进行了比较。L-743,872对白色念珠菌、光滑念珠菌、热带念珠菌、近平滑念珠菌和克柔念珠菌的唑类敏感和耐药菌株表现出最佳活性，而对克鲁斯念珠菌、葡萄牙念珠菌和季也蒙念珠菌的活性较低。

相似文献

1
In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species.新型抗真菌药L-743,872（一种 pneumocandin）对唑类敏感及耐药念珠菌属的体外活性
Antimicrob Agents Chemother. 1997 Jul;41(7):1612-4. doi: 10.1128/AAC.41.7.1612.
2
In vitro activity of a new pneumocandin antifungal agent, L-733,560 against azole-susceptible and -resistant Candida and Torulopsis species.新型肺炎球菌素抗真菌剂L-733,560对唑类敏感及耐药念珠菌属和球拟酵母菌属的体外活性
Antimicrob Agents Chemother. 1995 Dec;39(12):2689-91. doi: 10.1128/AAC.39.12.2689.
3
Candida and candidaemia. Susceptibility and epidemiology.念珠菌与念珠菌血症。药敏性与流行病学。
Dan Med J. 2013 Nov;60(11):B4698.
4
Evaluation of the Sensititre Yeast One microdilution method for susceptibility testing of Candida species to anidulafungin, caspofungin, and micafungin.评价Sensititre酵母微量稀释法对念珠菌属进行阿尼芬净、卡泊芬净和米卡芬净药敏试验的效果。
Rev Esp Quimioter. 2012 Dec;25(4):256-60.
5
In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital.卡泊芬净与两性霉素B、氟康唑和伊曲康唑相比，对土耳其一家大学医院分离出的念珠菌菌株的体外活性。
Med Mycol. 2005 Mar;43(2):171-8. doi: 10.1080/13693780410001731565.
6
[Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].念珠菌属对三唑类药物的抗真菌药敏谱：应用美国临床和实验室标准协会（CLSI）新的种特异性临床折点和流行病学截断值来表征抗真菌药物耐药性
Mikrobiyol Bul. 2016 Jan;50(1):122-32. doi: 10.5578/mb.10682.
7
Differential effects of the combination of caspofungin and terbinafine against Candida albicans, Candida dubliniensis and Candida kefyr.卡泊芬净与特比萘芬联合使用对白色念珠菌、都柏林念珠菌和克菲念珠菌的不同作用。
Int J Antimicrob Agents. 2004 May;23(5):520-3. doi: 10.1016/j.ijantimicag.2003.10.005.
8
In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.念珠菌属对卡泊芬净的体外敏感性：四年全球监测
J Clin Microbiol. 2006 Mar;44(3):760-3. doi: 10.1128/JCM.44.3.760-763.2006.
9
Caspofungin activity against clinical isolates of azole cross-resistant Candida glabrata overexpressing efflux pump genes.卡泊芬净对过表达外排泵基因的唑类交叉耐药光滑念珠菌临床分离株的活性。
J Antimicrob Chemother. 2006 Aug;58(2):458-61. doi: 10.1093/jac/dkl237. Epub 2006 Jun 6.
10
In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance.卡泊芬净（MK-0991）对表现出不同唑类耐药机制的白色念珠菌临床分离株的体外活性。
J Clin Microbiol. 2002 Jun;40(6):2228-30. doi: 10.1128/JCM.40.6.2228-2230.2002.

引用本文的文献

1
Nitric Oxide-Releasing Microparticles: A Novel Treatment for Onychomycosis.释放一氧化氮的微粒：甲癣的一种新型治疗方法。
Mol Pharm. 2025 Sep 1;22(9):5567-5575. doi: 10.1021/acs.molpharmaceut.5c00613. Epub 2025 Aug 21.
2
In Vitro Susceptibility Tests in the Context of Antifungal Resistance: Beyond Minimum Inhibitory Concentration in spp.抗真菌耐药背景下的体外药敏试验：超越某菌属的最低抑菌浓度
J Fungi (Basel). 2023 Dec 12;9(12):1188. doi: 10.3390/jof9121188.
3
Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antifungal Agents: A Review.EMA 批准的抗真菌药物研发过程中的临床前药代动力学/药效学研究和临床试验：综述。
Clin Pharmacokinet. 2024 Jan;63(1):13-26. doi: 10.1007/s40262-023-01327-2. Epub 2023 Nov 16.
4
A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects.近二十年获批上市的抗生素概述：回顾与展望。
Molecules. 2023 Feb 13;28(4):1762. doi: 10.3390/molecules28041762.
5
Characterization of lactic acid bacteria isolated from the poultry intestinal environment with anti-Salmonella activity in vitro.从禽类肠道环境中分离具有体外抗沙门氏菌活性的乳酸菌的特性研究。
Braz J Microbiol. 2023 Mar;54(1):435-447. doi: 10.1007/s42770-022-00860-9. Epub 2022 Nov 5.
6
Blad-Containing Oligomer Fungicidal Activity on Human Pathogenic Yeasts. From the Outside to the Inside of the Target Cell.含叶片的低聚物对人类致病酵母的杀菌活性。从靶细胞的外部到内部
Front Microbiol. 2016 Nov 14;7:1803. doi: 10.3389/fmicb.2016.01803. eCollection 2016.
7
The use of antifungal therapy in neonatal intensive care.新生儿重症监护中抗真菌治疗的应用。
Clin Perinatol. 2012 Mar;39(1):83-98. doi: 10.1016/j.clp.2011.12.008. Epub 2012 Jan 11.
8
Anidulafungin: an evidence-based review of its use in invasive fungal infections.阿尼芬净：关于其在侵袭性真菌感染中应用的循证综述
Core Evid. 2008 Jul 31;2(4):241-9.
9
Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.评估卡泊芬净对光滑念珠菌的体外动力学活性。
Antimicrob Agents Chemother. 2010 Jan;54(1):522-5. doi: 10.1128/AAC.01339-08. Epub 2009 Oct 19.
10
Caspofungin disk diffusion breakpoints and quality control.卡泊芬净纸片扩散法药敏试验折点及质量控制
J Clin Microbiol. 2008 Jun;46(6):1927-9. doi: 10.1128/JCM.00279-08. Epub 2008 Apr 9.

本文引用的文献

1
Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.1980 - 1990年美国医院获得性真菌感染流行病学的长期趋势。国家医院感染监测系统。
J Infect Dis. 1993 May;167(5):1247-51. doi: 10.1093/infdis/167.5.1247.
2
Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives.新型阳离子肺炎球菌糖肽菌素B（o）衍生物的合成及其抗真菌活性
J Med Chem. 1994 Jan 21;37(2):222-5. doi: 10.1021/jm00028a003.
3
Lysis of growing yeast-form cells of Candida albicans by echinocandin: a cytological study.棘白菌素对白色念珠菌生长中的酵母型细胞的溶解作用：一项细胞学研究。
Sabouraudia. 1981 Jun;19(2):97-110.
4
Echinocandin inhibition of 1,3-beta-D-glucan synthase from Candida albicans.棘白菌素对白色念珠菌1,3-β-D-葡聚糖合酶的抑制作用。
FEBS Lett. 1984 Jul 23;173(1):134-8. doi: 10.1016/0014-5793(84)81032-7.
5
Levels of gamma-glutamyltranspeptidase in cultured skin fibroblasts from cystinotics and normals.胱氨酸病患者和正常人培养的皮肤成纤维细胞中γ-谷氨酰转肽酶的水平。
Life Sci. 1980 Nov 24;27(21):1985-90. doi: 10.1016/0024-3205(80)90419-1.
6
Candidiasis in cancer patients.癌症患者的念珠菌病。
Am J Med. 1984 Oct 30;77(4D):13-9.
7
Fungal 1,3-beta-glucan synthase.真菌1,3-β-葡聚糖合酶
Methods Enzymol. 1987;138:637-42. doi: 10.1016/0076-6879(87)38057-7.
8
Fluconazole resistance in Candida glabrata.光滑念珠菌对氟康唑的耐药性。
Lancet. 1988 Dec 3;2(8623):1310. doi: 10.1016/s0140-6736(88)92919-4.
9
Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System.1980 - 1989年美国医院原发性血流感染的长期趋势。国家医院感染监测系统。
Am J Med. 1991 Sep 16;91(3B):86S-89S. doi: 10.1016/0002-9343(91)90349-3.
10
Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.接受氟康唑预防性治疗的骨髓移植和中性粒细胞减少患者中克鲁斯念珠菌感染增加。
N Engl J Med. 1991 Oct 31;325(18):1274-7. doi: 10.1056/NEJM199110313251803.